Dyne Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified: Brian Posner

Dyne Therapeutics, Inc.’s own tally for this item (“Elect Director: Brian Posner”): 148,535,323 for, 537,635 withheld, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 61,591,877 for, 1 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified: David Lubner

Dyne Therapeutics, Inc.’s own tally for this item (“Elect Director: David Lubner”): 136,331,376 for, 12,741,582 withheld, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 58,990,506 for, 2,601,352 withheld, 20 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified: Jason Rhodes

Dyne Therapeutics, Inc.’s own tally for this item (“Elect Director: Jason Rhodes”): 130,313,227 for, 18,759,731 withheld, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 57,384,998 for, 4,206,852 withheld, 28 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION TO PROVIDE FOR OFFICER EXCULPATION.

Dyne Therapeutics, Inc.’s own tally for this item (“The Company filed a certificate of amendment to its restated certificate of incorporation with the Secretary of State of the State of Delaware on June 8, 2026, to effect the Officer Exculpation Amendment. e) The stockhol”): 158,690,016 for, 25,660 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company filed a certificate of amendment to its restated certificate of incorporation with the Secretary of State of the State of Delaware on June 8, 2026, to effect the Officer Exculpation Amendment. e) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Co…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 58,403,330 for, 3,188,548 against.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 200,000,000 SHARES TO 400,000,000 SHARES.

Dyne Therapeutics, Inc.’s own tally for this item (“c) The stockholders of the Company approved an amendment to the Company's restated certificate of incorporation to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares (t”): 157,762,168 for, 913,118 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “c) The stockholders of the Company approved an amendment to the Company's restated certificate of incorporation to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares (the "Authorized Shares Amendment").”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 61,586,609 for, 5,270 against.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: TO VOTE, ON AN ADVISORY BASIS, TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

Dyne Therapeutics, Inc.’s own tally for this item (“b) The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.”): 147,732,142 for, 1,279,302 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “b) The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 62 managers: 61,577,713 for, 13,977 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 207 managers: 131,769,937 for, 718,313 against, 217,475 abstained, 1,036 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

The 63 asset managers below reported 61,591,878 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.